Dacoplice 30 mg Tablet
Brand Name: Dacoplice
Molecule: Dacomitinib
Strength: 30 mg
Quantity: 30 Tablets
Form: Tablet
Packaging Type: Bottle
Manufacturer/Marketed By: Pfizer
Country of Origin: India
Please fill in the details below, and we’ll get back to you as soon as possible
No similar products found.
Description
Dacoplice 30 mg Tablet contains dacomitinib, a targeted anticancer medicine classified as a tyrosine kinase inhibitor (TKI). It is used in the treatment of certain types of non-small cell lung cancer (NSCLC) that have specific genetic mutations in the epidermal growth factor receptor (EGFR). By targeting abnormal signaling pathways involved in tumor growth, dacomitinib may help slow the progression of cancer when used as prescribed by a qualified healthcare professional. Dacomitinib works by blocking the activity of EGFR proteins that promote cancer cell growth and survival. In patients whose tumors carry EGFR-activating mutations, this targeted therapy may help control disease progression. Dacoplice tablets are taken orally and are generally part of a long-term treatment plan managed by an oncologist. Because targeted therapies can affect multiple biological pathways, patients receiving
Benefits
-
Targets EGFR signaling, a key pathway involved in certain lung cancers
-
Oral targeted therapy that can be taken at home under medical supervision
-
Designed to inhibit multiple HER family receptors, potentially limiting tumor growth
-
Used in patients with confirmed EGFR mutations
-
Part of modern precision oncology treatment approaches
Indications and Usage
Dacoplice (dacomitinib) may be prescribed for:
-
Metastatic non-small cell lung cancer (NSCLC)
-
Patients whose tumors have EGFR exon 19 deletion or exon 21 L858R substitution mutations
-
Treatment in adults with EGFR-mutated NSCLC confirmed by appropriate diagnostic testing
Use is determined by an oncologist based on genetic testing results and clinical evaluation.
How it Works
Dacomitinib works by inhibiting the epidermal growth factor receptor (EGFR) and other members of the HER family of receptors, which are proteins that help regulate cell growth and division. In certain lung cancers, mutations in the EGFR gene lead to uncontrolled activation of these signaling pathways, causing cancer cells to grow and spread.
By blocking these receptors, dacomitinib disrupts signals that promote tumor cell proliferation and survival. This targeted mechanism may help slow cancer progression in patients with EGFR-mutated tumors when the medicine is used as prescribed and monitored by an oncology specialist.
Dosage & Administration
-
Dacoplice tablets are taken orally once daily, unless directed otherwise by a healthcare professional.
-
Tablets should be swallowed whole with water.
-
The medicine may be taken with or without food.
-
Dose adjustments may be required depending on tolerance and side effects.
-
Treatment duration is determined by the oncologist based on clinical response and disease progression.
Side Effects
Common side effects
-
Diarrhea
-
Skin rash or acne-like rash
-
Mouth sores (stomatitis)
-
Dry skin
-
Decreased appetite
-
Nail changes
Serious side effects
-
Severe diarrhea leading to dehydration
-
Lung inflammation (interstitial lung disease)
-
Severe skin reactions
-
Eye irritation or vision problems
-
Liver function abnormalities
Patients should contact their healthcare provider if severe symptoms occur.
Warning and Precaution
-
Risk of severe diarrhea and dehydration
-
Possible interstitial lung disease or lung inflammation
-
Skin reactions including rash or dermatitis
-
Potential eye disorders such as keratitis
-
Monitor liver function during treatment
-
Pregnancy should be avoided during therapy
-
Inform healthcare providers about all medicines and supplements before starting treatment
Patient Guidance
-
Take the medicine exactly as prescribed by your oncologist
-
Attend regular follow-up appointments and monitoring tests
-
Report symptoms such as severe diarrhea, breathing difficulty, or skin reactions
-
Inform your doctor about all medications and supplements you use
-
Maintain proper hydration, especially if experiencing diarrhea
-
Do not stop treatment without medical advice
Clinical Trial & Approvals
Dacomitinib has been evaluated in clinical trials for the treatment of EGFR-mutated non-small cell lung cancer. Studies such as the ARCHER 1050 trial demonstrated improved progression-free survival in certain patients compared with earlier therapies. Based on these results, dacomitinib has received regulatory approvals in several regions for the treatment of metastatic NSCLC with specific EGFR mutations.
References
-
U.S. Food and Drug Administration (FDA) – Dacomitinib Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288lbl.pdf -
European Medicines Agency (EMA) – Dacomitinib Product Information
https://www.ema.europa.eu -
National Cancer Institute – Dacomitinib Drug Information
https://www.cancer.gov -
Drugs.com – Dacomitinib Drug Information
https://www.drugs.com -
ClinicalTrials.gov – Studies Evaluating Dacomitinib
https://clinicaltrials.gov
Prescription & documentation note
Dacoplice 30 mg Tablet is typically supplied against a valid prescription. For international orders, patients may need to provide documents such as a licensed physician’s prescription, identification, and country-specific import documentation, depending on destination regulations. MedsMonk may assist with documentation guidance where applicable.
FAQ
What is Dacoplice 30 mg Tablet used for?
It is used to treat certain cases of metastatic non-small cell lung cancer with EGFR mutations, as prescribed by an oncologist.
What is the active ingredient in Dacoplice?
The active ingredient is dacomitinib, a tyrosine kinase inhibitor.
Is Dacoplice chemotherapy?
No. It is a targeted therapy that specifically inhibits EGFR signaling pathways.
How is Dacoplice taken?
It is usually taken once daily by mouth, with or without food.
Do patients need genetic testing before using dacomitinib?
Yes. Treatment is generally recommended for patients whose tumors have specific EGFR mutations confirmed by testing.
Can Dacoplice cause diarrhea?
Yes. Diarrhea is a common side effect and should be monitored during treatment.
Is a prescription required for Dacoplice?
Yes. It is a prescription-only oncology medicine.
How should Dacoplice tablets be stored?
Store at room temperature, away from moisture and excessive heat.
Related Products
Related Posts:
Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »May 18, 2026
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »May 14, 2026
FDA Fast-Tracks Plixorafenib for BRAF V600E–Mutated Brain Tumors
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 14, 2026.n n Brain tumors, especially high-grade
READ MORE »April 14, 2026
Only logged in customers who have purchased this product may leave a review.
Reviews
Clear filtersThere are no reviews yet.